Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed’s Substack by Patients Capital Management. In ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

Verona Pharma (NASDAQ: VRNA) jumped over 20% after Merck (NYSE: MRK) announced it was buying the company for $10 billion, or ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...